Rodríguez O, Alvarez F, Oltra R, Cereijo E, Latorre M M, Martínez H
Intensive Care Unit, Hospital Clínico Universitario, Valencia, Spain.
Rev Esp Quimioter. 2009 Jun;22(2):68-75.
All indications of linezolid (LZD) in Intensive Care Units (ICU) were included as cases in an observational, prospective and multicentre study. One hundred thirty-nine indications were analyzed. In most cases (92.7%), treatment for nosocomial infections was indicated. The most frequent infection was pneumonia (42.7%), followed by catheter-related bacteraemias (CRB). A total of 58.7% of the indications were empirical and in 45.7% of the cases the cultures confirmed infection by gram-positive cocci (GPC). In 43 cases (31.2%), the indication was made as a rescue measure (mainly due to clinical failure) in patients previously treated with glycopeptides. Of isolated GPC, 70.2% were methicillin-resistant. The cure rate of the population per intent-to-treat was 73.2%. Only one case of thrombocytopenia was recorded. Conclusions. LZD is used with a high degree of diagnostic safety. In the ICU, it is primarily indicated to treat pneumonias and CRB with good clinical and microbiological response. This antibiotic has acted as a good therapeutic resource against clinical failure in infections treated with glycopeptides.
重症监护病房（ICU）中利奈唑胺（LZD）的所有适应证均纳入一项观察性、前瞻性多中心研究的病例。共分析了139个适应证。大多数病例（92.7%）为医院感染的治疗。最常见的感染是肺炎（42.7%），其次是导管相关菌血症（CRB）。共有58.7%的适应证为经验性用药，45.7%的病例培养结果证实为革兰氏阳性球菌（GPC）感染。43例（31.2%）的适应证是作为对先前使用糖肽类药物治疗的患者的挽救措施（主要由于临床治疗失败）。分离出的GPC中，70.2%为耐甲氧西林菌株。按意向性治疗人群的治愈率为73.2%。仅记录到1例血小板减少症病例。结论。LZD的使用具有高度的诊断安全性。在ICU中，它主要用于治疗肺炎和CRB，临床和微生物学反应良好。这种抗生素对糖肽类药物治疗的感染临床失败起到了良好的治疗作用。
